• Recruiting

NCT04045028: Phase 1: Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma

Updated: May 26

NCT04045028: Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma


Tiragolumab

This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).


Sponsor

Genentech, Inc.


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04045028


Official Title: A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

First Posted : August 5, 2019


Click here to see details on ClinicalTrials.gov

 

Drug: Tiragolumab

Drug: Daratumumab/rHuPH20

Drug: Rituximab

Drug: Atezolizumab

 

Tiragolumab

Tiragolumab (Code C131291)

MTIG7192A

RG6058

Tiragolumab

TIRAGOLUMAB

 

Locations

United States, Colorado

United States, Georgia

United States, Maryland

United States, Missouri

United States, Ohio

United States, Pennsylvania

United States, Tennessee

United States, Virginia

Asia

Korea, Republic of



Posts Archive